Abstract
A growing number of clinical trials are evaluating the effects of stem cell therapy in patients with chronic ischemic heart dysfunction. As most of the clinical trials included a limited and different number of patients, various stem cell sources and several delivery approaches, results vary substantially between these studies. We analyse whether the assessment of myocardial viability may be important when evaluating effects of stem cell transplantation on parameters of left ventricular remodeling. Viability assessment could help to find the best type of stem cell and the best method of cell delivery to be used in chronic ischemic heart dysfunction.
Keywords: Stem cell, ischemic heart disease, viability, left ventricular function.
Cardiovascular & Hematological Disorders-Drug Targets
Title: Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability
Volume: 10 Issue: 3
Author(s): Pedro L. Sanchez, Ricardo Sanz-Ruiz, M. Eugenia Fernandez-Santos, Adolfo Villa, Enrique Gutierrez, Lucia Fernandez, Sandra Vazquez, M. Jose Lorenzo and Francisco Fernandez-Aviles
Affiliation:
Keywords: Stem cell, ischemic heart disease, viability, left ventricular function.
Abstract: A growing number of clinical trials are evaluating the effects of stem cell therapy in patients with chronic ischemic heart dysfunction. As most of the clinical trials included a limited and different number of patients, various stem cell sources and several delivery approaches, results vary substantially between these studies. We analyse whether the assessment of myocardial viability may be important when evaluating effects of stem cell transplantation on parameters of left ventricular remodeling. Viability assessment could help to find the best type of stem cell and the best method of cell delivery to be used in chronic ischemic heart dysfunction.
Export Options
About this article
Cite this article as:
L. Sanchez Pedro, Sanz-Ruiz Ricardo, Eugenia Fernandez-Santos M., Villa Adolfo, Gutierrez Enrique, Fernandez Lucia, Vazquez Sandra, Jose Lorenzo M. and Fernandez-Aviles Francisco, Stem Cell Therapy in Chronic Ischemic Heart Dysfunction with and Without Viability, Cardiovascular & Hematological Disorders-Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/1871529X11006030167
DOI https://dx.doi.org/10.2174/1871529X11006030167 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors
in the Context of Ischemic Heart Failure: A State-of-the-Art Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetic Cardiomyopathy: Clinical and Metabolic Approach
Current Vascular Pharmacology Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System
Current Pharmaceutical Design Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Immunologic Considerations in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Induction of Myocardial Fibrosis and Hypertrophy by Natriuretic Peptides
Vascular Disease Prevention (Discontinued) Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings
Current Neuropharmacology Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure
Current Drug Targets N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain
Current Pharmaceutical Design Obesity and Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Inflammatory Syndrome in Chronic Kidney Disease: Pathogenesis and Influence on Outcomes
Inflammation & Allergy - Drug Targets (Discontinued) Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart
Current Gene Therapy Organoselenium Compounds as Potential Therapeutic and Chemopreventive Agents: A Review
Current Medicinal Chemistry Advances in Drug Discovery against Neglected Tropical Diseases: Human African and American Trypanosomiasis
Current Medicinal Chemistry Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews